Development of solid lipid nanoparticles containing total flavonoid extract from Dracocephalum moldavica L. And their therapeutic effect against myocardial ischemia-reperfusion injury in rats

International Journal of Nanomedicine

Volumn 12, Issue , 2017, Pages 3253-3265

  Tan, Mei E ^a,b,c   He, Cheng Hui ^c   Jiang, Wen ^d   Zeng, Cheng ^b,c,d   Yu, Ning ^c   Huang, Wei ^b   Gao, Zhong Gao ^b   Xing, Jian Guo ^c  

^a SHIHEZI UNIVERSITY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c Xinjiang Institute of Materia Medica   (China)

^d XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Dracocephalum moldavica L; High shear homogeniza tion; Myocardial ischemic reperfusion injury; Pharmacodynamics; Solid lipid nanoparticles

Indexed keywords

CREATINE KINASE; FLAVONOID; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; LIPID; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; TOTAL FLAVONOID EXTRACT FROM DRACOCEPHALUM MOLDAVICA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; DRUG CARRIER; NANOPARTICLE; PLANT EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL COMPOSITE DESIGN; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSITY; DRACOCEPHALUM MOLDAVICA; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG LOADING; DRUG MECHANISM; DRUG RELEASE; DRUG SOLUBILITY; ELECTROCARDIOGRAM; ENTRAPMENT EFFICIENCY; HEART INFARCTION SIZE; HEART PROTECTION; HISTOPATHOLOGY; IN VITRO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MEDICINAL PLANT; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NANOEMULSION; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PHYSICAL PARAMETERS; PROCESS OPTIMIZATION; PROTEIN BLOOD LEVEL; RAT; RESPONSE SURFACE METHOD; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; CHEMISTRY; LAMIACEAE; MYOCARDIAL REPERFUSION INJURY; PROCEDURES; REPERFUSION INJURY; SOLUBILITY; SPRAGUE DAWLEY RAT; ULTRASOUND;

ANIMALS; DRUG CARRIERS; FLAVONOIDS; LAMIACEAE; LIPIDS; MALE; MYOCARDIAL REPERFUSION INJURY; NANOPARTICLES; PARTICLE SIZE; PLANT EXTRACTS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SOLUBILITY; ULTRASONICS;

EID: 85018972972     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S131893     Document Type: Article

References (38)

1. Najafi M, Ghasemian E, Fathiazad F, Garjani A. Effects of total extract of Dracocephalum moldavica on ischemia/reperfusion induced arrhythmias and infarct size in the isolated rat heart. Iran J Bas Med Sci. 2009;11(4):229-235.
2. Yuan Y, Xing J, Wang X, Lu P, Su H, Wen Z. [Study on the intestinal absorption of Dracocephalum total flavones in situ]. Chin Hosp Pharm J. 2011;31(20):1667-1670. Chinese.
3. Yang C, An X, Fu W, et al. [Relaxant effect of Dracocephalum flavonoids on rat thoracicaorta]. Acta Biophysica Sinica. 2010;26(4):334-340. Chinese.
4. Yang L, Xing J, He C, Yang P. [Chemical constituents of Dracomoldavica L. and their pharmacological activities]. World Clin Drug. 2013;34(4):226-231. Chinese.
5. Jiang J, Yuan X, Wang T, et al. Antioxidative and cardioprotective effects of total flavonoids extracted from Dracocephalum moldavica L. against acute ischemia/reperfusion-induced myocardial injury in isolated rat heart. Cardiovasc Toxicol. 2014;14(1):74-82.
6. Fan X, Cao W, Xing J, Guo X, Yuan Y, Wang X. [Protective effect of total flavones from Dracocephalum moldavica against myocardial ischemia-reperfusion injury in rats]. Chin Med. 2013;35:1625-1629. Chinese.
7. Hu X, Fan W, Yu Z, et al. Evidence does not support absorption of intact solid lipid nanoparticles via oral delivery. Nanoscale. 2016;8(13):7024-7035.
8. Hu X, Zhang J, Yu Z, et al. Environment-responsive aza-BODIPY dyes quenching in water as potential probes to visualize the in vivo fate of lipid-based nanocarriers. Nanomedicine. 2015;11(8):1939-1948.
9. Shangguan M, Qi J, Lu Y, Wu W. Comparison of the oral bioavailability of silymarin-loaded lipid nanoparticles with their artificial lipolysate counterparts: implications on the contribution of integral structure. Int J Pharm. 2015;489(1-2):195-202.
10. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formu lation: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231-248.
11. Yuan Y, Xing J, Wang L, Yao J, Wang X. [Study on the pharmacokanetic behavior of Dracocephalum moldavica L. Flavonoids in rat]. J Shehezi Univ. 2014;32:69-72. Chinese.
12. Mehnert W, Mäder K. Solid lipid nanoparticles: production, character ization and applications. Adv Drug Deliv Rev. 2011;47:165-196.
13. Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems an overview. Acta Pharm Sin B. 2013;3:361-372.
14. Melike Ü, Gülgün Y. Importance of solid lipid nanoparticles in various administration routes and future perspective. Nanomedicine. 2007;2:289-300.
15. Uner M. Preparation, characterization and physicochemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie. 2006;61:375-386.
16. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for par enteral drug delivery. Adv Drug Deliv Rev. 2003;56:1257-1272.
17. Yang J, Wang HX, Zhang YJ, et al. Astragaloside IV attenuates inflam matory cytokines by inhibiting TLR4/NF-κB signaling pathway in isoproterenol-induced myocardial hypertrophy. J Ethnopharmacol. 2013;150:1062-1070.
18. Stanley WC. Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies. J Cardiovasc Pharmacol Ther. 2004;9(suppl 1):S31-S45.
19. Guo J, Wang SB, Yuan TY, et al. Coptisine protects rat heart against myocardial ischemia/reperfusion injury by suppressing myocardial apoptosis and inflammation. Atherosclerosis. 2013;231(2):384-391.
20. Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. Inflammation in myocardial diseases. Circ Res. 2012;110(1):126-144.
21. Vander Heide RS, Steenbergen C. Cardioprotection and myocardial reperfusion: pitfalls to clinical application. Circ Res. 2013;113(4):464-477.
22. Liu CH, Wu CT. Optimization of nanostructured lipid carriers for lutein delivery. Colloids Surf A. 2010;353:149-156.
23. Zhang X, Liu J, Qiao H, et al. Formulation optimization of dihy droartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol. 2010;197:120-128.
24. Alex MR, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. 2011;42(1-2):11-18.
25. Mishra DK, Dhote V, Bhatnagar P, Mishra PK. Engineering solid lipid nanoparticles for improved drug delivery. Drug Deliv Transl Res. 2012;2:238-253.
26. Song R, Jin C, Zhou Y. [To determine content of total flavonoids and robinin-7-o-β-xylosylglucoside from Dracocephalum mololarie]. Chin J Exp Tradit Med Formulae. 2010;16:71-74. Chinese.
27. Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A. Solid lipid nanoparticles (SLN) of efavirenz as lymph targeting drug delivery system: elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm. 2015;495(1):439-446.
28. Teeranachaideekul V, Souto EB, Müller RH, Junyaprasert VB. Physi cochemical characterization and in vitro release studies of ascorbyl palmitate-loaded semi-solid nanostructured lipid carriers (NLC gels). J Microencapsul. 2008;25(2):111-120.
29. Kovacevic A, Savic S, Vuleta G, Müller RH, Keck CM. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int J Pharm. 2011;406(1-2):163-172.
30. Kullavadee KO, Uracha R, Smith SM. Effect of surfactant on char acteristics of solid lipid nanoparticles (SLN). Adv Mat Res. 2011;364:313-316.
31. Mehnert W, Mader K. Solid lipid nanoparticles: production, character ization and applications. Adv Drug Deliv Rev. 2011;47:165-196.
32. zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and releases mechanism. Eur J Pharm Biopharm. 1998;45:149-155.
33. Genc L, Dikmen G. Preparation and characterization of nocodazole-loaded solid lipid nanoparticles. Pharm Dev Technol. 2013;19(6):671-676.
34. Shah RM, Malherbe F, Daniel E, Palombo EA, Harding IH. Physico chemical characterization of solid lipid nanoparticles (SLNs) prepared by a novel microemulsion technique. J Colloid Interface Sci. 2014;428:286-294.
35. Puglia C, Offerta A, Rizza L, Zingale G, Bonina F, Ronsisvalle S. Optimization of curcumin loaded lipid nanoparticles formulated using high shear homogenization (HSH) and ultrasonication (US) methods. J Nanosci Nanotechnol. 2013;13(10):6888-6893.
36. Zur Muhlen A, Mehnert W. Drug release and release mechanisms of prednisolone loaded solid lipid nanoparticles. Pharmazie. 1998;53:552-555.
37. Zhang W, Li X, Ye T, et al. Design, characterization, and in vitro cel lular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posteriorcapsular opacification using response surface methodology. Int J Pharm. 2013;454(1):354-366.
38. Siddiqui A, Alayoubi A, EI-Malah Y, Nazzal S. Modeling the effect of sonication parameters on size and dispersion temperature of solid lipid nanoparticles (SLNs) by response surface methodology (RSM). Pharm Dev Technol. 2014;19(3):342-346.